Internal Medicine, Gastroenterology · Greenville, NC
NPI
1346406147
Since 2008
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
704 Wh Smith Blvd, Carolina Digestive Diseases, PA
Greenville, NC, 27834
Phone (252) 758-8181
Groups this clinician bills Medicare through
Medicare paid, 2024
$213K
2,544 services
Medicare patients, 2024
799
Average age 73
Drug cost, 2024
$4.0M
6,501 prescriptions
Company payments, 2025
$3,304
From 27 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Phillip J Goldstein was code 88305 (surgical pathology examination), 1,141 times for 480 patients. In total Phillip J Goldstein billed 2,544 services in 36 codes, and Medicare paid $213K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2010-06-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 88305 Surgical Pathology Examination | Office | 1,141 | 480 | $55.62 | $63K |
| 99214 Office E&M - Established | Office | 319 | 246 | $90.35 | $29K |
| 43239 Upper GI Endoscopy | Facility | 254 | 246 | $92.90 | $24K |
| 45380 Lower GI Endoscopy - Other | Facility | 203 | 202 | $122.23 | $25K |
| 99213 Office E&M - Established | Office | 167 | 157 | $57.71 | $9,637 |
| 45385 Colonoscopy - Lesion Removal | Facility | 120 | 119 | $210.52 | $25K |
| G0105 Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 61 | 61 | $182.20 | $11K |
| 43450 Digestive/Gastrointestinal | Facility | 51 | 51 | $31.66 | $1,615 |
| 99204 Office E&M - New | Office | 36 | 36 | $127.26 | $4,581 |
| 43249 Upper GI Endoscopy | Facility | 32 | 28 | $118.62 | $3,796 |
| 88312 Surgical Pathology Examination | Office | 28 | 26 | $89.25 | $2,499 |
| 45331 Lower GI Endoscopy - Other | Facility | 27 | 26 | $55.29 | $1,493 |
| 91065 Test - Miscellaneous | Office | 14 | 14 | $53.98 | $756 |
| 99203 Office E&M - New | Office | 13 | 13 | $75.77 | $985 |
| G0121 Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 12 | 12 | $182.61 | $2,191 |
By year: 2022 $301K for 5,357 services; 2023 $271K for 3,325 services; 2024 $213K for 2,544 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 88305 Surgical Pathology Examination | 1,141 | 480 | $55.62 | $63K |
| 88312 Surgical Pathology Examination | 28 | 26 | $89.25 | $2,499 |
Medicare prescription drug claims, 2024
In 2024, the drug Phillip J Goldstein prescribed most often to Medicare patients was Pantoprazole Sodium, with 1,208 prescriptions and refills. In total Phillip J Goldstein wrote 6,501 Medicare prescriptions that cost $4.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Pantoprazole Sodium Generic | 1,208 | 2,764 | 356 | $14K |
| Metoclopramide Hcl Generic | 885 | 985 | 245 | $4,038 |
| Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates | 569 | 569 | 566 | $38K |
| Omeprazole Generic | 451 | 997 | 123 | $6,148 |
| Famotidine Generic | 274 | 625 | 80 | $3,689 |
| Linzess Linaclotide | 219 | 391 | 65 | $204K |
| Colestipol Hcl Generic | 207 | 327 | 68 | $12K |
| Lansoprazole Generic | 198 | 426 | 58 | $7,217 |
| Dexlansoprazole Dr Dexlansoprazole | 179 | 342 | 39 | $56K |
| Esomeprazole Magnesium Generic | 152 | 317 | 36 | $4,189 |
| Xifaxan Rifaximin | 110 | 118 | 22 | $371K |
| Sucralfate Generic | 95 | 125 | 34 | $3,232 |
| Lubiprostone Generic | 89 | 131 | 23 | $13K |
| Mesalamine Generic | 87 | 122 | 17 | $30K |
| Dicyclomine Hcl Generic | 81 | 122 | 28 | $1,603 |
Brand drugs: 1,363 claims; generic drugs: 5,138 claims; opioid claims: 28.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Phillip J Goldstein $3,304 ($3,304 in general payments such as food, travel and fees) from 27 companies. The largest payer was Abbvie Inc. with $548.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 35 | $548 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 28 | $493 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 16 | $427 |
| Janssen Biotech, Inc. JNJ | 13 | $252 |
| Ardelyx, Inc. ARDX | 13 | $222 |
| Aimmune Therapeutics, Inc. | 10 | $204 |
| QOL Medical, LLC | 8 | $159 |
| Genzyme Corporation SNY | 5 | $143 |
| Gilead Sciences, Inc. GILD | 5 | $107 |
| Regeneron Healthcare Solutions, Inc. REGN | 4 | $106 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.